onr:"swepub:oai:DiVA.org:oru-79392"
Search: onr:"swepub:oai:DiVA.org:oru-79392" > IN-VITRO ACTIVITY O...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Meo, PaulSummit Therapeutics, Cambridge, UK (author)
IN-VITRO ACTIVITY OF SMT-571 AND COMPARATORS AGAINST CLINICAL ISOLATES AND REFERENCE STRAINS OF NEISSERIA GONORRHOEAE
- Article/chapterEnglish2019
Publisher, publication year, extent ...
- 2019-07-14
- BMJ Publishing Group Ltd,2019
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:oru-79392
- https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-79392URI
- https://doi.org/10.1136/sextrans-2019-sti.740DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Background: The emergence and spread of multidrug resistance to antibiotics used to treat gonorrhoea has resulted in a dramatic loss of effective regimens for the condition. Currently, the extended spectrum cephalosporin, ceftriaxone, is the only viable monotherapy option available, however, resistance to this last line treatment is now emerging globally. Herein, we assessed the in vitro activity of a novel small molecule antimicrobial with a new mechanism of action, SMT-571, against a large collection of N. gonorrhoeae clinical isolates and reference strains including numerous MDR and XDR gonococcal isolates.Methods: MICs (mg/L) of SMT-571 were determined by agar dilution according to current CLSI guidelines. The MICs of ceftriaxone, cefixime, azithromycin, ciprofloxacin, spectinomycin, tetracycline, and ampicillin were determined using the Etest method (AB bioMérieux, Marcy l’Etoile, France).Results: SMT-571 showed potent in vitro activity against all the tested N. gonorrhoeae isolates (n=262) with MICs ranging from 0.064 to 0.125 mg/L, and the MIC50, MIC90 and modal MIC were all 0.125 mg/L. The compound was not influenced by pre-existing resistance mechanisms with no cross-resistance or correlation between the MICs of SMT-571 and comparator agents being observed.Conclusion: This study is the first broad evaluation of the in vitro activities of a new mechanism, novel small molecule anti-microbial for the treatment of gonorrhoea. SMT-571 demonstrated highin vitroactivity against a large geographically, temporally and genetically diverse collection of clinical N. gonorrhoeae isolates and international reference strains, including various types of high-level resistant, MDR and XDR gonococcal isolates.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Mason, CliveSummit Therapeutics, Cambridge, UK (author)
- Khan, NawazSummit Therapeutics, Cambridge, UK (author)
- Unemo, Magnus,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län(Swepub:oru)muo (author)
- Jacobsson, Susanne,1974-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län(Swepub:oru)sajn (author)
- Summit Therapeutics, Cambridge, UKInstitutionen för medicinska vetenskaper (creator_code:org_t)
Related titles
- In:Sexually Transmitted Infections: BMJ Publishing Group Ltd95:Suppl. 1, s. A295-A2951368-49731472-3263
Internet link
Find in a library
- Sexually Transmitted Infections (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Meo, Paul
- Mason, Clive
- Khan, Nawaz
- Unemo, Magnus, 1 ...
- Jacobsson, Susan ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Infectious Medic ...
- Articles in the publication
- Sexually Transmi ...
- By the university
- Örebro University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
